Atty Dkt. No.: UCAL-138 DIV

USSN: 10/697,828

Group VI: Claims 25-27; method of diagnosing a disease comprising determining the

amount of glycosyl sulfotransferase polypeptide or nucleic acid; and

Group VII: Claim 29; non-human transgenic animal comprising a gent encoding the

glycosyl sulfotransferases.

Applicants hereby elect to prosecute the claims of Group I, claims 1-4, with traverse. As stated in the MPEP §803, if search and examination of an entire application can be made without serious burden, the examiner must examine the entire application on the merits, even though the entire application includes claims to independent or distinct inventions. It is the Applicants' position that it would not be unduly burdensome to perform a search on all of the claims together in the present application. Accordingly, Applicants traverse the restriction requirement.

Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter or any subject matter disclosed in this application during the pendency of this application.

Species Election

The Office Action stated that claims 1-29 are generic to a plurality of disclosed patentably distinct species comprising GST-4α, GST-4β, and GST-6.

Applicants elect GST- 4α . Of the elected claim group, claims 1-4 are readable on this species.

Atty Dkt. No.: UCAL-138 DIV

USSN: 10/697,828

II. CONCLUSION

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number UCAL-138 DIV.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 1, 2005

Paula A. Borden

Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\UCAL\138div\resp restr req.doc